RATIONALE: Although radiotherapy is effective in treating lung cancers, resultant pulmonary injury is the main obstacle. Pulmonary fibrosis is characterized by progressive worsening in pulmonary function leading to high incidence of death. Currently, however, there has been little progress in effective preventive and therapeutic strategies. OBJECTIVES: Previously, we reported that all-trans-retinoic acid (ATRA) reduced both irradiation-induced interleukin (IL)-6 production in lung fibroblasts and IL-6-dependent cell growth, and also directly inhibited the proliferation of lung fibroblasts after irradiation. In this study, we examined the preventive effect of ATRA on the progression of lung fibrosis both in irradiated and bleomycin-treated mice. MEASUREMENTS: We performed histologic examinations and quantitative measurements of IL-6, transforming growth factor (TGF)-beta(1), and collagen type Ialpha1 (COL1A1) in irradiated and bleomycin- treated mouse lung tissues with or without the administration of ATRA. RESULTS: Lethal irradiation effect was reduced by intraperitoneal administration of ATRA, and the overall survival rate at 16 wk was 30.0% without ATRA (n = 11), whereas it was 81.8% (n = 10) in the treatment group (p = 0.04). In vitro studies disclosed that the administration of ATRA reduced (1) irradiation-induced production of IL-6, TGF-beta(1), and collagen from IMR90 cells, and (2) IL-6-dependent proliferation and TGF-beta(1)-dependent transdifferentiation of the cells, which could be the mechanism underlying the preventive effect of ATRA on lung fibrosis. Furthermore, ATRA ameliorated bleomycin-induced fibrosis in mouse lung tissues. CONCLUSIONS: These data may provide a rationale to explore clinical use of ATRA for the prevention of radiation-induced lung fibrosis and other pathologic conditions involving pulmonary fibrosis.
RATIONALE: Although radiotherapy is effective in treating lung cancers, resultant pulmonary injury is the main obstacle. Pulmonary fibrosis is characterized by progressive worsening in pulmonary function leading to high incidence of death. Currently, however, there has been little progress in effective preventive and therapeutic strategies. OBJECTIVES: Previously, we reported that all-trans-retinoic acid (ATRA) reduced both irradiation-induced interleukin (IL)-6 production in lung fibroblasts and IL-6-dependent cell growth, and also directly inhibited the proliferation of lung fibroblasts after irradiation. In this study, we examined the preventive effect of ATRA on the progression of lung fibrosis both in irradiated and bleomycin-treated mice. MEASUREMENTS: We performed histologic examinations and quantitative measurements of IL-6, transforming growth factor (TGF)-beta(1), and collagen type Ialpha1 (COL1A1) in irradiated and bleomycin- treated mouse lung tissues with or without the administration of ATRA. RESULTS: Lethal irradiation effect was reduced by intraperitoneal administration of ATRA, and the overall survival rate at 16 wk was 30.0% without ATRA (n = 11), whereas it was 81.8% (n = 10) in the treatment group (p = 0.04). In vitro studies disclosed that the administration of ATRA reduced (1) irradiation-induced production of IL-6, TGF-beta(1), and collagen from IMR90 cells, and (2) IL-6-dependent proliferation and TGF-beta(1)-dependent transdifferentiation of the cells, which could be the mechanism underlying the preventive effect of ATRA on lung fibrosis. Furthermore, ATRA ameliorated bleomycin-induced fibrosis in mouse lung tissues. CONCLUSIONS: These data may provide a rationale to explore clinical use of ATRA for the prevention of radiation-induced lung fibrosis and other pathologic conditions involving pulmonary fibrosis.
Authors: Laura V Gatica; Liliana B Oliveros; Matías F Pérez Díaz; Nora S Domínguez; Miguel W Fornes; María S Gimenez Journal: Eur J Nutr Date: 2011-04-22 Impact factor: 5.614
Authors: Kurt H Albertine; Mar Janna Dahl; Linda W Gonzales; Zheng-Ming Wang; Drew Metcalfe; Dallas M Hyde; Charles G Plopper; Barry C Starcher; David P Carlton; Richard D Bland Journal: Am J Physiol Lung Cell Mol Physiol Date: 2010-04-09 Impact factor: 5.464
Authors: Marjolaine Roche; Prasad V S V Neti; Francis W Kemp; Amit Agrawal; Alicia Attanasio; Véronique Douard; Anjali Muduli; Edouard I Azzam; Edward Norkus; Michael Brimacombe; Roger W Howell; Ronaldo P Ferraris Journal: Am J Physiol Regul Integr Comp Physiol Date: 2009-11-11 Impact factor: 3.619
Authors: Khalid Puthawala; Nicos Hadjiangelis; Steven C Jacoby; Emmanuel Bayongan; Zhicheng Zhao; Zhiwei Yang; Mary Louise Devitt; Gerald S Horan; Paul H Weinreb; Matvey E Lukashev; Shelia M Violette; Kristen S Grant; Cristina Colarossi; Silvia C Formenti; John S Munger Journal: Am J Respir Crit Care Med Date: 2007-10-04 Impact factor: 21.405
Authors: Ruedi K Braun; Christina Ferrick; Paul Neubauer; Michael Sjoding; Anja Sterner-Kock; Martin Kock; Lei Putney; David A Ferrick; Dallas M Hyde; Robert B Love Journal: Inflammation Date: 2008-03-13 Impact factor: 4.092